Invention Grant
- Patent Title: Pyridine and pyrazine derivative for the treatment of CF
-
Application No.: US15156528Application Date: 2016-05-17
-
Publication No.: US10117858B2Publication Date: 2018-11-06
- Inventor: Urs Baettig , Kamlesh Bala , Emma Budd , Lee Edwards , Catherine Howsham , Glyn Alan Hughes , Darren Mark LeGrand , Katrin Spiegel
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Wendy F. Ballard
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61K31/443 ; A61K31/4439 ; A61K31/444 ; A61K31/4412 ; A61K31/4545 ; A61K31/4965 ; A61K31/497 ; A61K31/5377 ; A61K45/06 ; A61K31/4418 ; C07D213/81 ; C07D241/28 ; C07D401/04 ; C07D405/12 ; C07D413/04 ; C07D413/12 ; C07D213/38 ; C07D401/12 ; C07D403/12 ; C07D405/04 ; C07D241/26
Abstract:
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
Public/Granted literature
- US20170071919A1 Pyridine and Pyrazine derivative for the Treatment of CF Public/Granted day:2017-03-16
Information query
